A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

Inclusion Criteria: * Hospitalized non-ICU patients (age, \>= 18 years) * Clinical signs and symptoms of CAP, with PSI score IV or V * Radiologically confirmed evidence of a new and/or progressive infiltrate(s) * Requirement for initial parenteral therapy * At least 2 of the following conditions: * Productive or non productive cough with or without purulent or mucosus or mucopurulent sputum * Dyspnea and/or tachypnea (respiratory rate of \> 20 breaths/min) * Rigors and/or chills * Pleuritic chest pain * Auscultatory findings of rales and/or crackles on pulmonary examination and/or evidence of pulmonary consolidation * Fever (an oral temperature of \>= 38 °C, a rectal temperature of \>= 39 °C, or a tympanic temperature of \>= 38.5 °C) or hypothermia (rectal or core temperature of \< 35 °C), and a WBC count of \>= 10,000 cells/mm3 or \>= 15% immature neutrophils bands; regardless of peripheral WBC count) or leukopenia (total WBC count of \< 4500 cells/mm3) * Written informed consent Exclusion Criteria: * PSI Class I-III and V with need for ICU admission * Hospitalization for \> 48 hours before developing pneumonia, or discharge from hospital \< 30 days prior. Note: patients currently residing in residential long-term facilities can be enrolled in the study